Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington...(. Christophe Verny is part of CHU's Neur...),Health

Date:11/10/2008

. Christophe Verny is part of CHU's Neurology department (department manager: Professor Frederic Dubas), which is the reference center for numerous neuromuscular and neurodegenerative diseases. CHU's genetic and neurology teams have been labeled the "national reference center for neurodegenerative diseases." Patients suffering from genetic damages to the brain, spinal cord or periphery nerves are diagnosed and cared for by a multidisciplinary team coordinated by Dr. Christophe Verny, neurologist, and Professor Dominique Bonneau, geneticist.

For additional information, please visit http://www.chu-angers.fr.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: CHU D'Angers' ability to receive grant funding when requested and initiate a Phase II clinical study of DR Cysteamine in Huntington's Disease in 2009, if ever; that the potential benefits reflected in preclinical studies in Huntington's Disease preclinical models will be beneficial to patients with Huntington's Disease; cysteamine's ability to be neuroprotective in patients with Huntington's Disease; the Company's ability to successfully develop cysteamine or DR Cysteamine for any indication, including Huntington's Disease; the Company's ability to formulate DR Cysteamine to allow for less frequent dosing and a reduction in side effects; the Company's ability to manufacture DR Cysteamine in clinical quantities and be able to adequately supply planned clinical trials; and the Company's ability to comply with regulations to fulfill the criteria for maintaining Orphan Drug Designation for cysteamine or DR Cysteamine for the treatment of Huntington's Disease. These statements ar
'/>"/>

SOURCE Raptor Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Raptor Pharmaceuticals Provides Update on Targeting Platforms
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)